Breaking Finance News

Corvus Pharmaceuticals Inc (NASDAQ:CRVS) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Boasting a price of $16.37, Corvus Pharmaceuticals Inc (NASDAQ:CRVS) traded -0.49% lower on the day. With the last stock price close up 16.96% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Corvus Pharmaceuticals Inc has recorded a 50-day average of $14.88 and a two hundred day average of $14.00. Volume of trade was down over the average, with 19,106 shares of CRVS changing hands under the typical 23,198

Zacks Investment Research has upgraded Corvus Pharmaceuticals Inc (NASDAQ:CRVS) to Hold in a statement released on 10/3/2016.

Performance Chart

Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

With a total market value of $0, Corvus Pharmaceuticals Inc has with a one year low of $9.63 and a one year high of $17.77 .

A total of 1 brokerage has issued a ratings update on Corvus Pharmaceuticals Inc. zero brokerages rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally 0 brokers rating the stock a sell with a average stock price target of $24.00.

Brief Synopsis On Corvus Pharmaceuticals Inc (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. It is engaged in developing drugs designed to reprogram T-cells to restore the immune balance needed for tumor destruction. It offers approximately four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. Its product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. It focuses on evaluating CPI-444 in a multicenter Phase I/IB clinical trial in patients with various solid tumors. It offers a humanized anti-CD73 monoclonal antibody. It is evaluating orally administered antagonists that are selective for A2B, an alternate adenosine receptor. It focuses on Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *